179 related articles for article (PubMed ID: 28895096)
21. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial.
Man WH; Scheltema NM; Clerc M; van Houten MA; Nibbelke EE; Achten NB; Arp K; Sanders EAM; Bont LJ; Bogaert D
Lancet Respir Med; 2020 Oct; 8(10):1022-1031. PubMed ID: 32203712
[TBL] [Abstract][Full Text] [Related]
22. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
Romero JR
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
[TBL] [Abstract][Full Text] [Related]
23. Down syndrome as risk factor for respiratory syncytial virus hospitalization: A prospective multicenter epidemiological study.
Sánchez-Luna M; Medrano C; Lirio J;
Influenza Other Respir Viruses; 2017 Mar; 11(2):157-164. PubMed ID: 27611835
[TBL] [Abstract][Full Text] [Related]
24. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.
Frogel MP; Stewart DL; Hoopes M; Fernandes AW; Mahadevia PJ
J Manag Care Pharm; 2010; 16(1):46-58. PubMed ID: 20131495
[TBL] [Abstract][Full Text] [Related]
25. Palivizumab Prophylaxis among Infants at Increased Risk of Hospitalization due to Respiratory Syncytial Virus Infection in UAE: A Hospital-Based Study.
Elhalik M; El-Atawi K; Dash SK; Faquih A; Satyan AD; Gourshettiwar N; Khan A; Varughese S; Ramesh A; Khamis E
Can Respir J; 2019; 2019():2986286. PubMed ID: 31871513
[TBL] [Abstract][Full Text] [Related]
26. A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season.
Fernández P; Trenholme A; Abarca K; Griffin MP; Hultquist M; Harris B; Losonsky GA;
BMC Pediatr; 2010 Jun; 10():38. PubMed ID: 20525274
[TBL] [Abstract][Full Text] [Related]
27. Hospitalisations due to respiratory syncytial virus infection in children with Down syndrome before and after palivizumab recommendation in Japan.
Okamoto K; Morio T; Nakamura Y; Hataya H; Mizuta K; Mori M
Acta Paediatr; 2021 Apr; 110(4):1299-1306. PubMed ID: 33119906
[TBL] [Abstract][Full Text] [Related]
28. Risk factors for hospitalisation due to respiratory syncytial virus infection in children receiving prophylactic palivizumab.
Chida-Nagai A; Sato H; Sato I; Shiraishi M; Sasaki D; Izumi G; Yamazawa H; Cho K; Manabe A; Takeda A
Eur J Pediatr; 2022 Feb; 181(2):539-547. PubMed ID: 34417646
[TBL] [Abstract][Full Text] [Related]
29. One-year observational study of palivizumab prophylaxis on infants at risk for respiratory syncytial virus infection in Latin America.
Castillo LM; Bugarin G; Arias JC; Barajas Rangel JI; Serra ME; Vain N
J Pediatr (Rio J); 2017; 93(5):467-474. PubMed ID: 28236418
[TBL] [Abstract][Full Text] [Related]
30. A post-incorporation study on the use of palivizumab in the Brazilian public health system.
Batista JDL; Ferreira MAP; Xavier CDS; Souza ITA; Cruz LN; Polanczyk CA
Rev Inst Med Trop Sao Paulo; 2021; 63():e5. PubMed ID: 33533808
[TBL] [Abstract][Full Text] [Related]
31. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
;
Pediatrics; 2014 Aug; 134(2):e620-38. PubMed ID: 25070304
[TBL] [Abstract][Full Text] [Related]
32. Detection and control of a nosocomial respiratory syncytial virus outbreak in a stem cell transplantation unit: the role of palivizumab.
Kassis C; Champlin RE; Hachem RY; Hosing C; Tarrand JJ; Perego CA; Neumann JL; Raad II; Chemaly RF
Biol Blood Marrow Transplant; 2010 Sep; 16(9):1265-71. PubMed ID: 20304082
[TBL] [Abstract][Full Text] [Related]
33. Impact of the Withdrawal of Palivizumab Immunoprophylaxis on the Incidence of Respiratory Syncytial Virus (RSV) Hospitalizations Among Infants Born at 33 to 35 Weeks' Gestational Age in the Province of Quebec, Canada: The RSV-Quebec Study.
Papenburg J; Defoy I; Massé E; Caouette G; Lebel MH
J Pediatric Infect Dis Soc; 2021 Apr; 10(3):237-244. PubMed ID: 32530035
[TBL] [Abstract][Full Text] [Related]
34. Prophylaxis protects infants with congenital heart disease from severe forms of RSV infection: an Italian observational retrospective study : Palivizumab prophylaxis in children with congenital heart disease.
Ratti C; Greca AD; Bertoncelli D; Rubini M; Tchana B
Ital J Pediatr; 2023 Jan; 49(1):4. PubMed ID: 36631870
[TBL] [Abstract][Full Text] [Related]
35. Adherence to Palivizumab for Respiratory Syncytial Virus Prevention in the Canadian Registry of Palivizumab.
Chan P; Li A; Paes B; Abraha H; Mitchell I; Lanctôt KL;
Pediatr Infect Dis J; 2015 Dec; 34(12):e290-7. PubMed ID: 26780032
[TBL] [Abstract][Full Text] [Related]
36. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes.
Oh PI; Lanctôt KL; Yoon A; Lee DS; Paes BA; Simmons BS; Parison D; Manzi P;
Pediatr Infect Dis J; 2002 Jun; 21(6):512-8. PubMed ID: 12182374
[TBL] [Abstract][Full Text] [Related]
37. Universal palivizumab prophylaxis for children with Down syndrome in Japan: analysis with interrupted time-series.
Takeuchi M; Kawakami K
Hum Vaccin Immunother; 2021 Apr; 17(4):1235-1238. PubMed ID: 32961094
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of Palivizumab Immunoprophylaxis for Reducing Severe RSV Outcomes in Children with Immunodeficiencies: A Systematic Review.
Reicherz F; Abu-Raya B; Akinseye O; Rassekh SR; Wiens MO; Lavoie PM
J Pediatric Infect Dis Soc; 2024 Feb; 13(2):136-143. PubMed ID: 38279954
[TBL] [Abstract][Full Text] [Related]
39. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
;
Pediatrics; 2014 Aug; 134(2):415-20. PubMed ID: 25070315
[TBL] [Abstract][Full Text] [Related]
40. Association Between Updated Guideline-Based Palivizumab Administration and Hospitalizations for Respiratory Syncytial Virus Infections.
Grindeland CJ; Mauriello CT; Leedahl DD; Richter LM; Meyer AC
Pediatr Infect Dis J; 2016 Jul; 35(7):728-32. PubMed ID: 27078122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
